在Apixaban相关出血后恢复血静的FXa绕过剂的工程和评估
Wojciech Jankowski1, Stepan S Surov1, Nancy E Hernandez1
1Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD, USA.
Nature communications
|May 9, 2024
概括
研究人员设计了新的FXa变体,以逆转直接口服抗凝剂 (DOAC) 的作用,减少与向FXa的DOAC相关的出血风险. 这些新型药物为现有的逆转疗法提供了潜在的更安全的替代方案.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 针对Xa因子 (FXa) 的直接口服抗凝剂 (DOACs) 对于预防和治疗血栓塞栓性疾病至关重要.
- 虽然有效,但针对FXa的DOACs (FXaDOACs) 具有抗凝剂相关出血的风险.
- 目前的逆转药物,如安德克萨内特阿尔法,具有包括复杂剂量和血栓形成风险在内的局限性.
研究的目的:
- 通过计算设计和设计具有抗凝固逆转活性的新型FXa变体.
- 评估这些工程FXa变体作为潜在的更安全的替代品来逆转FXaDOACs.
- 在临床前模型中评估设计的FXa变体的疗效和安全性.
主要方法:
- 利用计算设计和蛋白质工程来创建FXa变体.
- 评估了DOACs与工程FXa变体的结合亲和力.
- 在接受阿皮克萨班治疗的小鼠模型中评估了FXa变体的酶活性和血静恢复能力.
主要成果:
- 设计的FXa变体对FXaDOACs具有较低的结合亲和力.
- 工程变体保留了FXa酶活性.
- 这些FXa变体通过恢复血液静止,有效地减少了小鼠的阿皮克萨班相关出血.
- 与安德克萨内特阿尔法不同,设计的药物没有抑制TFPI,这表明潜在地改善了血栓形成特征.
结论:
- 新的FXa变种已成功设计和设计用于FXaDOAC逆转.
- 这些变种显示出作为管理FXaDOAC相关出血的有效和可能更安全的药物具有前景.
- 与现有的逆转疗法相比,由于其作用机制,设计的FXa变体可能会提供更好的安全性概况.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
01:16Clot Retraction and Fibrinolysis
5.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.3K
01:28Esophageal Varices-II: Clinical Features and Management
60
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
60